Ed Geistlich S��hne AG F��r Chemische Industrie is a multi-national private company headquartered in Schlieren, Switzerland. The firm operates as holding company.

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in developing a platform for nitric oxide generators and delivery systems. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Freedom Waves Srl is an Italian private company. The firm manufactures ultrasound based technology and medical devices.

Enceladus is a drug development company, which started as a spin-off from Utrecht University, The Netherlands. Enceladus is product-oriented and aims at finding innovative combinations of existing drugs and drug carrier systems. With this approach it can effectively design new pharmaceuticals for which clinical development is relatively straightforward. Enceladus is embedded in an extensive academic network with strong expertise in colloidal drug carriers for the design of novel anti-inflammatory products. Enceladus operates in the fields of inflammation, autoimmune diseases and cancer, which are chronic, progressive, and debilitating, if not deadly diseases. Despite considerable progress in the treatment of these diseases, there remains a large need for further improvement Enceladus primary focus is on the preclinical and early clinical development of its products. The company seeks interaction with larger pharmaceutical companies for late stage development and marketing. Enceladus has recently obtained funding enabling it to successfully complete several clinical phase IIa studies in different indications.

IBEX Technologies Inc is a Canada-based Company that manufactures and markets enzymes for biomedical use. The company produces a family of high purity recombinant glycosaminoglycan (GAG) lyases, namely Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC and Chondroitinase B. It also produces a series of arthritis assays which are used by pharmaceutical companies for research purposes. The Company has proprietary expression system in Flavobacterium heparinum and produces these enzymes at the highest purity. Heparinase I rapidly and specifically neutralize both unfractionated heparin as well as low molecular weight heparin, allowing baseline hemostasis to be monitored in the presence of these anticoagulants.

Fidia Farmaceutici SpA manufactures pharmaceutical products. The firm's platform technology level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering therapeutic categories. The company was founded in 1946 and is headquartered in Abano Terme, Italy.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

IFO - Istituti Fisioterapici Ospitalieri is a private company headquartered in Rome, Italy. The firm engages in research for cancer and provides healthcare services.

The Texas A&M University System creates a seamless pathway for students to earn an associate and bachelor’s degree in related fields

Guangzhou Fuda Cancer Hospital is a tertiary specialized cancer hospital which is affiliated with the Health Department of Guangdong Province in China. It was designated a national key clinical (cancer) hospital by the National Health and Family Planning Commission in 2011. The same year, Guangzhou Fuda Cancer Hospital was honored with National Trustworthy Private Hospital by the National Institute of Hospital Administration. In 2012, China Hospital Association rated Guangzhou Fuda Cancer Hospital as China Public Confidence Model Hospital. It was accredited by JCI in 2014.

Universiteit Utrecht Holding BV provides portfolio management and commercial development services. It strengthen and broaden cooperation among partners encompassing companies, governmental institutions, cultural and social organizations. The company was founded in 1996 and is headquartered in Utrecht, the Netherlands.

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the 3rd company of its kind ever created, and has a rich tradition of innovation and commercialization. Through our efforts to identify and create breakthrough scientific research at Hebrew University, we aspire to advance commercial solutions to the most pressing global challenges facing humanity. (Contact Tamir Huberman) Some of our well-known spin-off companies include Mobileye, Orcam, Collplant, Qlight, and Briefcam. Yissum’s business partners span the globe and include companies such as Novartis, Johnson & Johnson, Merck, Intel, Google, Boston Scientific, ICL and many more. Since its inception, Yissum has registered 10,000+ patents covering 2,800+ inventions; licensed 900 technologies and produced 130+ spin-off companies.

TOPGEN is committed to tumor precision medical products and engages in precision medicine. Continuous industry research and development, as well as the construction of an industry ecology, will protect human health. It adheres to international norms, standards, and industry guidelines, as well as introduces and develops international advanced technologies and testing methods. It serves large tertiary hospitals, specialized hospitals, general hospitals, research institutions, and pharmaceutical companies in China.

Suzhou Gena Biotechnology Co., Ltd., established on 2016-11-16, Business scope includes biotechnology,Technology development in the field of biomedicine and medical devices,technical consulting,technology transfer,Technical Services;Research and development of computer hardware and software,Sales and technical service;Self-operated and agent import and export business of various commodities and technologies;Instrumentation and accessories,Sales of laboratory consumables;electronic product,teaching facility,Mechanical and electrical product sales and technical services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. It is a biotechnology company, engages in developing immunotherapeutic agents for various clinical conditions in the United States. The company’s product candidates include activated natural killer candidates for the treatment of virally-induced cancers, such as human papilloma virus-induced cervical, and head and neck cancers; ebola; and serious viral, fungal, and bacterial infections, as well as that is in Phase II clinical trials for the treatment of polyoma virus-induced merkel cell carcinoma.

Tianjin Zhengzhong Technology Co., Ltd., established on 2011-05-19, The scope of business includes the development of breeding technology,Ganoderma lucidum,vegetable,fruit planting,Sales,Commodity packaging processing,freshwater fish,shrimp,crab farming,Sales,Wholesale and retail of prepackaged food and bulk food,domestic cigarettes,rice,flour,Labor protection products,Daily necessities,Hotel Supplies,Wholesale and retail of measuring instruments,Agricultural product deep processing technology development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)